Marshall Wace’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $67.1M | Buy |
508,977
+160,134
| +46% | +$21.2M | 0.07% | 269 |
|
|
2025
Q4 | $49.5M | Buy |
348,843
+251,554
| +259% | +$36.4M | 0.05% | 345 |
|
|
2025
Q3 | $13.7M | Buy |
97,289
+55,640
| +134% | +$7.54M | 0.01% | 805 |
|
|
2025
Q2 | $5.23M | Buy |
+41,649
| New | +$4.78M | 0.01% | 1115 |
|
|
2025
Q1 | – | Sell |
-2,425
| Closed | -$331K | – | 2931 |
|
|
2024
Q4 | $331K | Buy |
+2,425
| New | +$300K | ﹤0.01% | 2204 |
|
|
2024
Q2 | – | Sell |
-32,976
| Closed | -$4.55M | – | 2813 |
|
|
2024
Q1 | $4.55M | Buy |
+32,976
| New | +$4.5M | 0.01% | 1035 |
|
|
2023
Q2 | – | Sell |
-162,683
| Closed | -$16.5M | – | 2799 |
|
|
2023
Q1 | $16.5M | Buy |
162,683
+132,237
| +434% | +$13.8M | 0.04% | 528 |
|
|
2022
Q4 | $3.64M | Buy |
+30,446
| New | +$3.57M | 0.01% | 1390 |
|
|
2022
Q1 | – | Sell |
-10,553
| Closed | -$898K | – | 3774 |
|
|
2021
Q4 | $898K | Buy |
+10,553
| New | +$971K | ﹤0.01% | 2525 |
|
|
2021
Q1 | – | Sell |
-79,044
| Closed | -$7.58M | – | 2735 |
|
|
2020
Q4 | $7.58M | Sell |
79,044
-67,899
| -46% | -$6.56M | 0.04% | 430 |
|
|
2020
Q3 | $14.1M | Buy |
+146,943
| New | +$17M | 0.09% | 226 |
|
|
2020
Q1 | – | Sell |
-4,395
| Closed | -$473K | – | 1921 |
|
|
2019
Q4 | $473K | Sell |
4,395
-62,171
| -93% | -$6.51M | ﹤0.01% | 1194 |
|
|
2019
Q3 | $6M | Buy |
+66,566
| New | +$6.22M | 0.05% | 451 |
|
|
2019
Q2 | – | Sell |
-375,076
| Closed | -$33M | – | 1668 |
|
|
2019
Q1 | $33M | Sell |
375,076
-332,399
| -47% | -$27.8M | 0.31% | 55 |
|
|
2018
Q4 | $50.5M | Buy |
707,475
+626,995
| +779% | +$60.1M | 0.52% | 29 |
|
|
2018
Q3 | $9.89M | Buy |
+80,480
| New | +$9.13M | 0.08% | 305 |
|
|
2018
Q2 | – | Sell |
-8,144
| Closed | -$675K | – | 796 |
|
|
2018
Q1 | $675K | Buy |
+8,144
| New | +$688K | 0.03% | 302 |
|
|
2017
Q3 | – | Sell |
-10,093
| Closed | -$464K | – | 394 |
|
|
2017
Q2 | $464K | Sell |
10,093
-14,535
| -59% | -$705K | 0.02% | 247 |
|
|
2017
Q1 | $1.06M | Sell |
24,628
-326,954
| -93% | -$14M | 0.05% | 200 |
|
|
2016
Q4 | $13.6M | Buy |
351,582
+141,893
| +68% | +$6.42M | 0.09% | 259 |
|
|
2016
Q3 | $10.6M | Sell |
209,689
-21,436
| -9% | -$1.07M | 0.08% | 272 |
|
|
2016
Q2 | $10.5M | Buy |
+231,125
| New | +$10.6M | 0.09% | 242 |
|
|
2014
Q4 | – | Sell |
-51,860
| Closed | -$813K | – | 904 |
|
|
2014
Q3 | $813K | Sell |
51,860
-64,504
| -55% | -$964K | 0.01% | 578 |
|
|
2014
Q2 | $1.73M | Buy |
+116,364
| New | +$1.64M | 0.03% | 418 |
|
Other funds holding NBIX
VPM
VCM
Marshall Wace's NBIX Position: Q1 2026 in Review
Marshall Wace increased its Neurocrine Biosciences (NBIX) stake by 46% in Q1 2026, buying an estimated $21.2M and bringing the position to 508,977 shares worth $67.1M. The position accounts for 0.07% of the portfolio, ranked #269.
Marshall Wace first reported a position in NBIX in Q2 2014 and has held it in 24 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Marshall Wace held 508,977 shares of Neurocrine Biosciences worth $67.1M as of Q1 2026.
- Marshall Wace bought 160,134 Neurocrine Biosciences shares in Q1 2026, an estimated $21.2M.
- Neurocrine Biosciences made up 0.07% of Marshall Wace's portfolio in Q1 2026, its #269 holding.
- Marshall Wace first reported a position in Neurocrine Biosciences in Q2 2014 and has held it in 24 quarters since.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.